PhenomeX announces the release of SpotLight™ Human Lambda reagent for the Beacon® platform to accelerate cell line development workflows

PhenomeX Inc., a functional cell biology company, is pleased to announce that GSK will present data on the SpotLight™ Human Lambda reagent for the Beacon® platform at the 16th annual Conference on Protein Expression in Animal Cells, which is being held in Sitges, Spain from September 24-28, 2023. The goal of the PEACe Conference is to continue the tradition of bringing together scientists from academia and industry to share knowledge in the field of recombinant protein expression.

Molly Robinson, a senior scientist with GSK, will present data demonstrating how the SpotLight Human Fc, SpotLight Human Kappa and SpotLight Human Lambda reagents can be used in cell line development productivity assays on the Beacon platform. In this study, as an early access PhenomeX customer, GSK screened clones secreting IgG Lambda light chain monoclonal antibodies and clones secreting bispecific lambda-kappa antibodies.

Additionally, the GSK team was able to characterize a variety of molecular formats using the library of SpotLight reagents, and they are excited to continue using these reagents to investigate complex molecular candidates.

PhenomeX's fluorescent SpotLight reagents, which are non-destructive and certified as animal- component free, allow early productivity and product quality screens to be run in parallel across thousands of clonal populations. 

  • SpotLight™ Human Fc reagent binds to the Fc region of human antibodies
  • SpotLight™ Human Kappa reagent binds to the kappa light chain of human antibodies
  • Soon-to-be released SpotLight™ Human Lambda reagent binds to the lambda light chain of human antibodies

As demonstrated by GSK, these reagents can be used individually for screening of monospecific antibodies or in combination to screen bispecific lambda-kappa antibodies.

The SpotLight Human Lambda reagent further expands the range of molecular formats we can screen using the Beacon; thus enabling a flexible Cell Line Development process, to support our rapidly diversifying Biopharmaceutical portfolio.

Dr. Robyn Emmins, Scientific Director for Cell Line Development, GSK

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bruker Cellular Analysis. (2023, September 25). PhenomeX announces the release of SpotLight™ Human Lambda reagent for the Beacon® platform to accelerate cell line development workflows. News-Medical. Retrieved on July 23, 2024 from https://www.news-medical.net/news/20230925/PhenomeX-announces-the-release-of-SpotLighte284a2-Human-Lambda-reagent-for-the-Beaconc2ae-platform-to-accelerate-cell-line-development-workflows.aspx.

  • MLA

    Bruker Cellular Analysis. "PhenomeX announces the release of SpotLight™ Human Lambda reagent for the Beacon® platform to accelerate cell line development workflows". News-Medical. 23 July 2024. <https://www.news-medical.net/news/20230925/PhenomeX-announces-the-release-of-SpotLighte284a2-Human-Lambda-reagent-for-the-Beaconc2ae-platform-to-accelerate-cell-line-development-workflows.aspx>.

  • Chicago

    Bruker Cellular Analysis. "PhenomeX announces the release of SpotLight™ Human Lambda reagent for the Beacon® platform to accelerate cell line development workflows". News-Medical. https://www.news-medical.net/news/20230925/PhenomeX-announces-the-release-of-SpotLighte284a2-Human-Lambda-reagent-for-the-Beaconc2ae-platform-to-accelerate-cell-line-development-workflows.aspx. (accessed July 23, 2024).

  • Harvard

    Bruker Cellular Analysis. 2023. PhenomeX announces the release of SpotLight™ Human Lambda reagent for the Beacon® platform to accelerate cell line development workflows. News-Medical, viewed 23 July 2024, https://www.news-medical.net/news/20230925/PhenomeX-announces-the-release-of-SpotLighte284a2-Human-Lambda-reagent-for-the-Beaconc2ae-platform-to-accelerate-cell-line-development-workflows.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Berkeley Lights Launches Cell Line Development 2.0 Workflow to Find Top Clones for Complex Antibody Therapeutics